233 related articles for article (PubMed ID: 19632953)
1. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Wohl DA; Kendall MA; Andersen J; Crumpacker C; Spector SA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Lurain N; Jabs D; Benson C; Keiser P; Jacobson MA;
HIV Clin Trials; 2009; 10(3):143-52. PubMed ID: 19632953
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies.
Wohl DA; Zeng D; Stewart P; Glomb N; Alcorn T; Jones S; Handy J; Fiscus S; Weinberg A; Gowda D; van der Horst C
J Acquir Immune Defic Syndr; 2005 Apr; 38(5):538-44. PubMed ID: 15793363
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
[TBL] [Abstract][Full Text] [Related]
5. Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era.
Mizushima D; Nishijima T; Gatanaga H; Tsukada K; Teruya K; Kikuchi Y; Oka S
PLoS One; 2013; 8(5):e65348. PubMed ID: 23724140
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
7. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
8. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
Bigliano P; Calcagno A; Lucchini A; Audagnotto S; Montrucchio C; Marinaro L; Alcantarini C; Ghisetti V; Di Perri G; Bonora S
Antivir Ther; 2018; 23(5):451-456. PubMed ID: 29372886
[TBL] [Abstract][Full Text] [Related]
9. Distribution and determinants of cytomegalovirus induced end organ disease/s among people living with HIV/AIDS in a poor resource setting: observation from India.
Chakraborty A; Mahapatra T; Mahapatra S; Ansari S; Siddhanta S; Banerjee S; Banerjee D; Sarkar RN; Guha SK; Chakraborty N
PLoS One; 2015; 10(2):e0117466. PubMed ID: 25679798
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Disease in HIV-infected Children-A Single-Centre Clinical Experience over 23 Years.
Suri D; Jindal AK; Gupta A; Gupta A; Bajgai P; Singh R; Singh MP; Minz RW; Arora S; Singh S
J Trop Pediatr; 2018 Jun; 64(3):215-224. PubMed ID: 29873796
[TBL] [Abstract][Full Text] [Related]
11. CMV pp65 antigen testing is of limited utility in the diagnosis of concomitant CMV disease in HIV-infected patients in the HAART era.
Skiest DJ; Crosby C
J Clin Virol; 2003 Oct; 28(2):203-13. PubMed ID: 12957190
[TBL] [Abstract][Full Text] [Related]
12. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy.
Deayton JR; Prof Sabin CA; Johnson MA; Emery VC; Wilson P; Griffiths PD
Lancet; 2004 Jun; 363(9427):2116-21. PubMed ID: 15220032
[TBL] [Abstract][Full Text] [Related]
13. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
[TBL] [Abstract][Full Text] [Related]
14. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1.
Komanduri KV; Viswanathan MN; Wieder ED; Schmidt DK; Bredt BM; Jacobson MA; McCune JM
Nat Med; 1998 Aug; 4(8):953-6. PubMed ID: 9701250
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
Weinberg A; Tierney C; Kendall MA; Bosch RJ; Patterson-Bartlett J; Erice A; Hirsch MS; Polsky B;
J Infect Dis; 2006 Feb; 193(4):488-93. PubMed ID: 16425127
[TBL] [Abstract][Full Text] [Related]
16. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of quantitative plasma cytomegalovirus DNA PCR for cytomegalovirus end-organ diseases in patients with HIV-1 infection.
Mizushima D; Nishijima T; Yashiro S; Teruya K; Kikuchi Y; Katai N; Oka S; Gatanaga H
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):140-6. PubMed ID: 25590268
[TBL] [Abstract][Full Text] [Related]
18. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy.
Deayton J; Mocroft A; Wilson P; Emery VC; Johnson MA; Griffiths PD
AIDS; 1999 Jul; 13(10):1203-6. PubMed ID: 10416523
[TBL] [Abstract][Full Text] [Related]
19. [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy].
Reus S; Portilla J; Gimeno A; Sánchez-Payá J; García-Henarejos JA; Martínez-Madrid O; Usó J; Roca B; Galindo MJ; López-Aldeguer J
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):142-9. PubMed ID: 14987534
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infection: the point in 2001.
Salmon-Ceron D
HIV Med; 2001 Oct; 2(4):255-9. PubMed ID: 11737406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
